Eli Lilly and Company $LLY Stock Bought by Cooper Financial Group

Cooper Financial Group boosted its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 5,776 shares of the company’s stock after acquiring an additional 502 shares during the period. Cooper Financial Group’s holdings in Eli Lilly and Company were worth $6,683,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also modified their holdings of the company. Elm3 Financial Group LLC increased its holdings in Eli Lilly and Company by 3.8% in the third quarter. Elm3 Financial Group LLC now owns 4,204 shares of the company’s stock valued at $4,864,000 after buying an additional 152 shares during the last quarter. Canandaigua National Trust Co of Florida acquired a new stake in Eli Lilly and Company in the third quarter valued at $19,155,000. Persium Advisors LLC lifted its holdings in Eli Lilly and Company by 5.5% during the 3rd quarter. Persium Advisors LLC now owns 327 shares of the company’s stock worth $378,000 after buying an additional 17 shares during the last quarter. Baring Financial LLC lifted its holdings in Eli Lilly and Company by 13.5% during the 3rd quarter. Baring Financial LLC now owns 453 shares of the company’s stock worth $524,000 after buying an additional 54 shares during the last quarter. Finally, Bath Savings Trust Co boosted its position in shares of Eli Lilly and Company by 1.0% during the 3rd quarter. Bath Savings Trust Co now owns 26,487 shares of the company’s stock worth $30,648,000 after acquiring an additional 252 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $29.46 on Wednesday, hitting $1,186.95. The stock had a trading volume of 2,300,611 shares, compared to its average volume of 2,974,313. The stock has a market cap of $1.12 trillion, a price-to-earnings ratio of 39.83, a P/E/G ratio of 1.40 and a beta of 0.46. The company has a current ratio of 1.35, a quick ratio of 1.00 and a debt-to-equity ratio of 1.41. Eli Lilly and Company has a 52-week low of $783.85 and a 52-week high of $1,292.65. The company’s 50 day moving average price is $1,173.51 and its 200 day moving average price is $1,094.59.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm’s quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter last year, the business posted $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts anticipate that Eli Lilly and Company will post 36.66 EPS for the current year.

Insider Transactions at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the completion of the sale, the chief accounting officer owned 1,526 shares in the company, valued at $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Anat Hakim sold 5,000 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the transaction, the executive vice president directly owned 11,875 shares in the company, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 13,500 shares of company stock worth $15,958,170. Insiders own 0.14% of the company’s stock.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Healthcare was one of the market’s few strong sectors, with Eli Lilly among the leaders. The relative strength likely reflects continued investor preference for defensive healthcare companies and Lilly’s strong growth profile. Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets
• Positive Sentiment: Analysts and commentators highlighted growth opportunities beyond Mounjaro and Zepbound, including oncology, immunology, neuroscience, insulin and other pipeline programs. This supports the view that Lilly’s long-term outlook is not dependent on a single obesity-drug franchise. Where Will Eli Lilly Stock Be in 5 Years? Follow the Pipeline Beyond Zepbound
• Positive Sentiment: Recent data for Lilly’s oral GLP-1 candidate Foundayo reportedly showed greater weight loss and better blood-sugar control than oral semaglutide in adults with type 2 diabetes. A successful oral product could broaden access and add another major growth driver, though the analysis still requires further validation. Foundayo Showed Better Results Than Oral Semaglutide in a New Analysis
• Positive Sentiment: Retatrutide, Lilly’s next-generation triple-hormone obesity candidate, was identified as a potentially underappreciated catalyst. Reported trial weight loss has exceeded Zepbound’s results, and a regulatory filing is expected in early 2027. Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026
• Neutral Sentiment: Investment commentary remains divided: Lilly’s rapid revenue and earnings growth support premium valuation, but the stock trades near 40 times trailing earnings, leaving limited room for execution errors. Eli Lilly: Impressive Growth, Questionable Valuation
• Negative Sentiment: The World Health Organization’s new childhood-obesity guidelines could increase scrutiny of obesity-drug use in younger patients and create additional regulatory or adoption hurdles for Lilly and Novo Nordisk. Eli Lilly and Novo Face New Pressure from WHO’s Childhood Obesity Guidelines

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on LLY. Citigroup raised their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Cantor Fitzgerald upped their price target on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an “overweight” rating in a report on Thursday, August 6th. Truist Financial increased their price target on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the company a “buy” rating in a research note on Friday, August 7th. Leerink Partners raised their price objective on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the stock an “outperform” rating in a report on Thursday, June 25th. Finally, Sanford C. Bernstein boosted their price objective on shares of Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-five have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,312.36.

Eli Lilly and Company Profile

Eli Lilly and Company is a global pharmaceutical company headquartered in Indianapolis, Indiana. Founded in 1876 by Colonel Eli Lilly, the company researches, develops, manufactures and markets medicines for a range of conditions, including diabetes, obesity, cancer, immunological disorders, neurological diseases and pain.

Its products include Mounjaro and Zepbound, which contain tirzepatide and are used for type 2 diabetes and chronic weight management, respectively. Other key medicines include Trulicity for diabetes, Verzenio for certain breast cancers, Taltz for inflammatory and autoimmune conditions, Humalog insulin, and Kisunla for early symptomatic Alzheimer’s disease.